Form D — Quince Therapeutics, Inc.
0000912282-26-000811 · filed Jun 11, 2026
Offering amounts describe securities offered; amounts sold are issuer-reported as of each filing. Amendments can repeat earlier amounts. We do not add these figures into a capital-raised total. Missing amounts are not zero. Data coverage and methodology · How to interpret the amounts.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Reported offering amount
- $7,387,671
- Reported amount sold
- $0
- Minimum investment
- $0
- Investors
- 66
- Sales commission
- $1,800,000
- Finders' fees
- $0
Issuer
- Name
- Quince Therapeutics, Inc.
- CIK
- 1662774
- Entity
- Corporation
- Jurisdiction
- CALIFORNIA
- Year incorporated
- —
- Address
- 611 Gateway Blvd., Suite 273
South San Francisco, CA 94080 - Phone
- 415-910-5717
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Dirk Thye · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Brigette Roberts · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Charles Ryan · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Brendan Hannah · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
David Lamond · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Christopher Senner · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
June Bray · DirectorSouth San Francisco, CA Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗